We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




MRSA AI Diagnostics Software Helps Enhance Microbiology Lab Efficiency and Workflow

By LabMedica International staff writers
Posted on 29 May 2023
Print article
Image: BD Kiestra MRSA imaging application helps enhance microbiology laboratory efficiency and workflow (Photo courtesy of BD)
Image: BD Kiestra MRSA imaging application helps enhance microbiology laboratory efficiency and workflow (Photo courtesy of BD)

Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant risk in hospital environments, leading to serious complications like bloodstream or surgical-site infections, sepsis, and even death. Lab tests are necessary to confirm whether an infection is due to MRSA, and the capacity to conduct these tests efficiently and effectively could profoundly influence patient care. However, labs often face hurdles such as fluctuating sample volumes, staff shortages, financial constraints from budget cuts, and shifting diagnostic methods. To address these challenges and facilitate efficient, timely, and cost-effective clinical bacteriological testing, a new solution now offers comprehensive lab automation for clinical microbiology laboratories.

Becton, Dickinson and Company’s (BD, Franklin Lakes, NJ, USA) new BD Kiestra MRSA imaging application employs artificial intelligence (AI) to analyze bacterial growth and release negative samples with minimal human intervention. The BD Kiestra MRSA application employs AI to automate the traditionally laborious and time-consuming task of inspecting Petri dishes to ascertain bacterial growth, allowing medical lab scientists and technicians to devote more time to high-priority analyses.

The application can evaluate individual samples or group together numerous plates showing non-significant growth for batch review and release of negative results, potentially easing the administrative load on technicians. The MRSA imaging application utilizes AI algorithms to identify specific culture characteristics on the BBL CHROMagar MRSA II plate. Based on this information and analysis by BD Synapsys informatics, plate images are automatically arranged and sorted into meaningful worklists for lab scientists and technicians. This AI-driven imaging application, backed by the BD BBL CHROMagar MRSA II screening plates and powered by BD Synapsys Informatics Solution, is compatible with both standalone BD Kiestra ReadA systems and track-based BD Kiestra lab automation solutions.

"The pandemic created significant and ongoing labor challenges in laboratories, and reading plates is a labor-intense, potentially error-prone process in microbiology," said Nikos Pavlidis, vice president and general manager for Diagnostics at BD. "The use of this imaging application to automatically organize specimens in meaningful worklists helps use limited laboratory staff more efficiently and allows lab personnel to bring their expertise to bear on more critical and complex specimens."

Related Links:
BD 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.